Market Research Logo

Payer Insights: MS [2016]: Bulletin #3

Payer Insights: MS [2016]: Bulletin #3


Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways by which Biogen could retain market share of Tecfidera.

Business Questions:

  • How do payers react to the recent approval of ocrelizumab?
  • How is ocrelizumab likely to be covered in the US?
  • How do US payers feel about ocrelizumab’s competitive pricing? Are there any apprehensions?
  • How do payers react to the delay in launch of generic Copaxone 40mg/ml?
  • According to payers, what can Teva do to retain its market share of branded Copaxone 40mg/ml?
  • According to payers, what can Biogen do to retain market share of Tecfidera?

Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report